Spanish pharmaceutical company Zendal and IAVI partner to advance the TB vaccine candidate MTBVAC into efficacy trials

-- TB kills 1.4 million people a year, an infectious disease toll only recently surpassed by COVID-19.
-- COVID-19 has reversed years of progress in TB response, costing additional lives and adding to the urgency of the global TB problem.
-- MTBVAC is a highly promising vaccine candidate that has the potential to be used as an alternative to BCG vaccination in infants and for prevention of TB disease in adolescents and adults.